Innogen Pharma jostles for a slice of the weight-loss market 减肥药市场逐渐内卷 银诺医药和时间赛跑
The developer of diabetes and anti-obesity drugs has applied for a Hong Kong IPO as it prepares for battle in a crowded arena. 银诺医药自主研发的GLP-1候选药物预计将在明年上半年上市，或让这个已经相当竞争的市场更加内卷化。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.